LifeVantage Co. (NASDAQ:LFVN) Shares Acquired by Susquehanna International Group LLP

Susquehanna International Group LLP raised its holdings in LifeVantage Co. (NASDAQ:LFVN - Free Report) by 83.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 128,082 shares of the company's stock after purchasing an additional 58,279 shares during the period. Susquehanna International Group LLP owned about 1.02% of LifeVantage worth $2,245,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LFVN. Copeland Capital Management LLC purchased a new stake in LifeVantage during the 4th quarter valued at approximately $65,000. Hillsdale Investment Management Inc. lifted its stake in shares of LifeVantage by 7.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company's stock worth $258,000 after purchasing an additional 1,000 shares in the last quarter. Barclays PLC increased its holdings in LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company's stock valued at $507,000 after buying an additional 11,608 shares during the last quarter. Ritholtz Wealth Management grew its holdings in shares of LifeVantage by 65.2% during the fourth quarter. Ritholtz Wealth Management now owns 47,348 shares of the company's stock valued at $830,000 after purchasing an additional 18,682 shares during the last quarter. Finally, EAM Investors LLC acquired a new stake in LifeVantage in the fourth quarter worth approximately $1,056,000. Institutional investors and hedge funds own 35.32% of the company's stock.

LifeVantage Price Performance

Shares of LFVN traded up $0.39 during trading hours on Wednesday, hitting $12.52. 77,427 shares of the stock were exchanged, compared to its average volume of 139,310. The firm has a market capitalization of $157.54 million, a P/E ratio of 22.35 and a beta of 0.41. The business has a 50-day moving average of $14.08 and a 200-day moving average of $16.31. LifeVantage Co. has a fifty-two week low of $5.22 and a fifty-two week high of $27.38.

LifeVantage (NASDAQ:LFVN - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. The company had revenue of $58.44 million during the quarter, compared to analysts' expectations of $60.99 million. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 30th will be given a dividend of $0.045 per share. The ex-dividend date is Friday, May 30th. This represents a $0.18 dividend on an annualized basis and a yield of 1.44%. This is an increase from LifeVantage's previous quarterly dividend of $0.04. LifeVantage's dividend payout ratio (DPR) is presently 26.09%.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum began coverage on shares of LifeVantage in a research note on Tuesday, January 14th. They issued a "buy" rating and a $35.00 target price for the company.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.